(Press-News.org) LEXINGTON, Ky. (Sept. 8, 2014) – A new study by University of Kentucky researchers has identified a novel molecule named Arylquin 1 as a potent inducer of Par-4 secretion from normal cells. Par-4 is a protein that acts as a tumor suppressor, killing cancer cells while leaving normal cells unharmed.
Normal cells secrete small amounts of Par-4 on their own, but this amount is not enough to kill cancer cells. Notably, if Par-4 secretion is suppressed, this leads to tumor growth.
Published in Nature Chemical Biology, the UK study utilized lab cultures and animal models to show that low levels of Arylquin 1 induced Par-4 secretion without causing harm to the producer cells.
Additionally, researchers found that Par-4 is bound to a protein called vimentin, which contributes to tumor metastasis. Arylquin 1 binds to vimentin, displacing the Par-4 for secretion -- which means it may also be useful for inhibitiing the spread of cancer.
These findings have strong implications for the development of future cancer treatments, as researchers are now focusing on developing Arylquin 1 into a drug to inhibit both primary and metastatic tumors.
"We found that Par-4 is inactivated by pro-metastasis proteins such as vimentin," said Vivek Rangnekar, UK professor and Alfred Cohen Chair in Oncology Research in the Department of Radiation Medicine. "This implies that by using small molecule drugs that target metastasis proteins, we may be able to both inhibit the spread of cancer while also releasing the tumor suppressor -- Par-4 -- to then induce the death of the cancerous cells."
Rangnekar, who also serves as Associate Director for the UK Markey Cancer Center, initially discovered the Par-4 gene in 1994. Working closely with UK medicinal chemist David Watt and a multidisciplinary team across the UK campus, their labs are developing secretagogues that can cause elevated secretion of Par-4 for the inhibition of primary and metastatic tumors.
INFORMATION:
This study was funded by grants from the National Cancer Institute, the National Center for Research Resources, and the UK Center for Clinical and Translational Science.
UK study identifies molecule that induces cancer-killing protein
2014-09-07
ELSE PRESS RELEASES FROM THIS DATE:
Each day in the hospital raises risk of multidrug-resistant infection
2014-09-07
If a patient contracts an infection while in the hospital, each day of hospitalization increases by 1% the likelihood that the infection will be multidrug-resistant, according to research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) an infectious disease meeting of the American Society for Microbiology.
Researchers from the Medical University of South Carolina gathered and analyzed historical data from 949 documented cases of Gram-negative infection at their academic medical center. In the first few days of hospitalization ...
New antifungal as effective as existing drugs with fewer adverse events
2014-09-07
A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.
"There is a growing need for new antifungal therapies like isavuconazole because serious fungal infections caused by Aspergillus and other molds are on the rise due to the increasing numbers of immunosuppressed ...
Inexpensive lab test identifies resistant infections in hours
2014-09-07
Researchers from Oregon State Public Health Lab have modified the protocol for a relatively new test for a dangerous form of antibiotic resistance, increasing its specificity to 100 percent. Their research, confirming the reliability of a test that can provide results in hours and is simple and inexpensive enough to be conducted in practically any clinical laboratory was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.
The test, called Carba NP, originally ...
61 percent fall in female genital warts due to free HPV vaccine
2014-09-07
GPs in Australia are managing 61 per cent less cases of genital warts among young women since the introduction of the national human papillomavirus (HPV) vaccination program, a new study from the University of Sydney reveals.
The study, which reviewed more than a million patient encounters between 2000 and 2012, showed a significant year-on-year reduction in the management rate of genital warts in women aged 15-27 years since the vaccination program started. The findings are published in PLOS One journal.
"The results show that the program has been a widespread success," ...
Flour identified as the main cause of occupational asthma in France
2014-09-07
Munich, Germany: Flour has been identified as the main cause of occupational asthma in France, closely followed by cleaning products.
A new study, which was presented at the European Respiratory Society's International Congress today (07 September 2014), analysed all cases of occupational asthma in France. The research, which is the largest of its kind to be undertaken in France, aimed to understand who was most affected by the condition and what the main causes were.
Data were collected over a 3-year period from a network of respiratory doctors specialised in occupational ...
Electronic nose can detect sub-groups of asthma in children
2014-09-07
Munich, Germany: An electronic nose can be used to successfully detect different sub-groups of asthmatic children, according to a new study.
The new research, presented at the European Respiratory Society (ERS) International Congress in Munich today (7 September 2014), is part of the U-BIOPRED* project to learn more about different types of asthma to ensure better diagnosis and treatment for each person.
Healthcare professionals now understand that there are many different types of asthma and that it affects people in very different ways. Current research efforts are ...
Timing of food intake could impact the effectiveness of TB treatment
2014-09-07
Munich, Germany: The timing of food intake in the early phase of TB treatment could have a negative impact on the effectiveness of TB treatment.
A new study, presented at the European Respiratory Society (ERS) International Congress in Munich today (07 September 2014), suggests that eating food just before taking a TB drug could reduce the effectiveness of the medicine.
Researchers conducted a small study looking at 20 patients who were about to begin treatment for TB for the first time. They were given the usual course of TB drugs, including isoniazid, rifampicin, ...
Patients call for health professionals to discuss care needs in life-threatening illnesses
2014-09-07
Munich, Germany: Patients with COPD would like healthcare professionals to discuss palliative care needs in more detail, according to a new study.
Palliative care refers to care that is focused on making a person comfortable and relieving symptoms, rather than treating a condition. It is often connected with end-of-life care; although it can refer to any stage of care for any life-threatening condition.
The research, presented at the European Respiratory Society (ERS) International Congress in Munich today (7 September 2014), investigated the preferences of patients ...
Mandatory policy boosts flu vaccination rates among health care workers
2014-09-07
DETROIT – Hospitals can greatly improve their flu vaccination rate among health care workers by using a mandatory employee vaccination policy, according to a Henry Ford Health System study.
Citing its own data, Henry Ford researchers say the health system achieved employee vaccination rates of 99 percent in the first two years of its mandatory policy, in which annual vaccination compliance is a condition of employment.
Nationally, 63 percent of health care workers were immunized against the flu in the past two years, according to the Centers for Disease Control and ...
New single-dose influenza drug appears safe and effective
2014-09-06
An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms. Researchers report their findings today at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an infectious diseases meeting of the American Society for Microbiology (ASM).
"Based on clinical data, peramivir is the first neuraminidase inhibitor (NAI) that ...